6/ Also striking: 251 trials of anti-PD1/L1 in combo w anti-CTLA-4; 170 trials of anti-PD1/L1 in combo w chemo. Are these the right #s? Need for coordination across landscape? Tang et al ask the right questions. /end
A point I neglected to flag: 2/3 of trials across immuno-onc landscape are investigator-initiated, often single-center and small. My prediction: relatively few will contribute meaningful knowledge.
What think you of the Tang et al immuno-oncology story, @VinayPrasad82?
• • •
Missing some Tweet in this thread? You can try to
force a refresh